MedTrace Logo

Sutent Rechallenge In mRCC Patients

NCT01827254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2015-04-30

Study results available
· View outcomes & findings →

Summary

Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

OTHER

sunitinib: observational study

Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827254 on ClinicalTrials.gov